{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T13:16:25Z","timestamp":1788182185423,"version":"build-2803163510"},"reference-count":39,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Cancer poses a major challenge to global health, impacting individuals, communities and societies worldwide. A significant proportion of global morbidity and mortality from neoplasms is accounted for by gastrointestinal tumors, due to their high incidence and lethality. Capecitabine, an oral antineoplastic agent, has brought advances in treatment, but requires caution regarding adherence and adverse events. In this context, it is believed that pharmaceutical care can significantly contribute to optimizing therapy and promoting better clinical outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>The aim of this study is to assess the advantages of pharmaceutical care for patients with gastric cancer who are being treated with capecitabine.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A multicentre, prospective, longitudinal study was conducted with patients with gastric cancer using capecitabine. Patients were randomised into two groups, namely control (pharmaceutical guidance) and intervention (pharmaceutical care). Sociodemographic, clinical, and therapeutic data were collected, and adverse events were identified, classified and analysed, with impacts such as dose suspension or reduction, emergencies, hospitalisations and use of additional drugs being considered. Quality of life was assessed before and after treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Thirty-one patients were selected, 16 of whom were in the intervention group. This group completed more treatment cycles, although it had a higher number of adverse events, with less severity. All patients who received pharmaceutical care were adherent to their treatment. In contrast, patients who did not receive pharmaceutical care had more suspensions and dose reductions. They also had a significant worsening of overall functional capacity. In addition, their symptoms such as nausea, vomiting, and diarrhea were aggravated. In the intervention group, however, there was an improvement in these symptoms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The study highlights the importance of pharmaceutical care in capecitabine treatment, especially in the management of adverse events, treatment adherence and promotion of quality of life. Despite the small sample size, the results reinforce the role of the pharmacist in the care of these patients and indicate the need for further studies with larger samples.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10781552261481842","type":"journal-article","created":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T15:36:51Z","timestamp":1787845011000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Pharmaceutical care in patients with gastric cancer treated with capecitabine: A randomized clinical trial"],"prefix":"10.1177","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0285-5179","authenticated-orcid":false,"given":"Patr\u00edcia Kaiser","family":"Pedroso Cava","sequence":"first","affiliation":[{"name":"Universidade Federal Fluminense"},{"name":"Universidade Federal Fluminense"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0904-2787","authenticated-orcid":false,"given":"Camille Nigri","family":"Cursino","sequence":"additional","affiliation":[{"name":"Universidade Federal Fluminense"},{"name":"Universidade Federal Fluminense"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5447-0847","authenticated-orcid":false,"given":"Larissa Dos","family":"Santos Sebould Marinho","sequence":"additional","affiliation":[{"name":"Universidade Federal Fluminense"},{"name":"Universidade Federal Fluminense"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-4006-0537","authenticated-orcid":false,"given":"Ana Clara","family":"Duarte Dos Santos","sequence":"additional","affiliation":[{"name":"Universidade Federal Fluminense"},{"name":"Universidade Federal Fluminense"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8818-6633","authenticated-orcid":false,"given":"Ariela Dutra","family":"Norberto De Oliveira","sequence":"additional","affiliation":[{"name":"Universidade Federal Fluminense"},{"name":"Universidade Federal Fluminense"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-2404-7425","authenticated-orcid":false,"given":"Larissa Rodrigues","family":"Nascimento","sequence":"additional","affiliation":[{"name":"Hospital Universit\u00e1rio Clementino Fraga Filho, Universidade Federal do Rio de Janeiro"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1130-1760","authenticated-orcid":false,"given":"Vanessa Cristiane","family":"Da Silva Ferreira","sequence":"additional","affiliation":[{"name":"Universidade Federal Fluminense"},{"name":"Universidade Federal Fluminense"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1795-2337","authenticated-orcid":false,"given":"Dulce Helena","family":"Nunes Couto","sequence":"additional","affiliation":[{"name":"Instituto Nacional de C\u00e2ncer"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1987-3584","authenticated-orcid":false,"given":"Jessica Pronestino","family":"De Lima Moreira","sequence":"additional","affiliation":[{"name":"Universidade Federal Fluminense"},{"name":"Universidade Federal Fluminense"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0527-4417","authenticated-orcid":false,"given":"Tha\u00edsa Amorim","family":"Nogueira","sequence":"additional","affiliation":[{"name":"Universidade Federal Fluminense"},{"name":"Universidade Federal Fluminense"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0272-4777","authenticated-orcid":false,"given":"Selma Rodrigues","family":"De Castilho","sequence":"additional","affiliation":[{"name":"Universidade Federal Fluminense"},{"name":"Universidade Federal Fluminense"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2026-1510","authenticated-orcid":false,"given":"Sabrina","family":"Calil-Elias","sequence":"additional","affiliation":[{"name":"Universidade Federal Fluminense"},{"name":"Universidade Federal Fluminense"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,8,27]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834"},{"key":"e_1_3_2_3_2","unstructured":"Minist\u00e9rio da Sa\u00fade Instituto Nacional de C\u00e2ncer Jos\u00e9 Alencar Gomes da Silva Minist\u00e9rio da Sa\u00fade Instituto Nacional de C\u00e2ncer. 2023."},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-024-19104-6"},{"key":"e_1_3_2_5_2","unstructured":"Nicole McMillian NR MaryElizabeth Stein M Ajani JA et al. NCCN Guidelines Version 2.2025 Gastric Cancer Continue NCCN Guidelines Panel Disclosures. 2025. https:\/\/www.nccn.org\/home\/member-."},{"key":"e_1_3_2_6_2","unstructured":"Menon G El-Nakeep S Babiker HM. Gastric Cancer. 2025."},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1177\/17588359211009001"},{"key":"e_1_3_2_8_2","article-title":"Atua\u00e7\u00e3o e avan\u00e7os do profissional farmac\u00eautico no \u00e2mbito oncol\u00f3gico","volume":"10","author":"Santos CdN","year":"2021","unstructured":"Santos CdN, Pinheiro Neto JC, Sousa IJO, et al. Atua\u00e7\u00e3o e avan\u00e7os do profissional farmac\u00eautico no \u00e2mbito oncol\u00f3gico. Research, Society and Development 2021; 10: e9210915794.","journal-title":"Research, Society and Development"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1177\/1078155218798150"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40268-016-0154-8"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1177\/1078155221989420"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1177\/1078155219833441"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1200\/OP.20.00947"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.31557\/APJCP.2024.25.11.3877"},{"key":"e_1_3_2_15_2","volume-title":"Coordinated and reviewed by Maria Funchal Witzel","author":"Dader MF","year":"2019","unstructured":"Dader MF, Mu\u00f1oz PA, Martinez-Martinez F. Aten\u00e7\u00e3o farmac\u00eautica: servi\u00e7os farmac\u00eauticos orientados ao paciente. In: Coordinated and reviewed by Maria Funchal Witzel. RCN Editora, 2019, pp.360 p."},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.japh.2019.07.008"},{"key":"e_1_3_2_17_2","doi-asserted-by":"crossref","unstructured":"ISOPP Standards for the safe handling of cytotoxics. J Oncol Pharm Pract 2022; 28: S1\u2013S126.","DOI":"10.1177\/10781552211070933"},{"key":"e_1_3_2_18_2","unstructured":"Medication Safety in Polypharmacy. http:\/\/apps.who.int\/bookorders. 2019."},{"key":"e_1_3_2_19_2","unstructured":"Cancer Institute N. Common Terminology Criteria for Adverse Events (CTCAE) Common Terminology Criteria for Adverse Events (CTCAE) v5.0. 2017. https:\/\/www.meddra.org\/."},{"key":"e_1_3_2_20_2","doi-asserted-by":"crossref","unstructured":"Aaronson NK Ahmedzai S Bergman B et al. The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology. https:\/\/academic.oup.com\/jnci\/article-abstract\/85\/5\/365\/972260.","DOI":"10.1093\/jnci\/85.5.365"},{"key":"e_1_3_2_21_2","first-page":"1","article-title":"EORTC QLQ-C30 scoring manual: this manual is intended to assist users with scoring procedures for the QLQ-C30 version 3 and earlier, and the QLQ supplementary modules","volume":"30","author":"Fayers PM","year":"2001","unstructured":"Fayers PM, Neil A, Kristin B, et al. EORTC QLQ-C30 scoring manual: this manual is intended to assist users with scoring procedures for the QLQ-C30 version 3 and earlier, and the QLQ supplementary modules. EORTC 2001; 30: 1\u201367.","journal-title":"EORTC"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02776"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1155\/2023\/4946642"},{"key":"e_1_3_2_24_2","doi-asserted-by":"crossref","unstructured":"Cunningham D Starling N Rao S et al. Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer. 2008. www.nejm.org.","DOI":"10.1056\/NEJMoa073149"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-007-0515-7"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2017-0558"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1177\/10781552211017199"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1590\/2177-9465-ean-2018-0017"},{"key":"e_1_3_2_29_2","article-title":"Pharmaceutical cancer care for haematology patients on oral anticancer drugs: Findings from an economic, clinical and organisational analysis","volume":"31","author":"Zerbit J","year":"2022","unstructured":"Zerbit J, Kroemer M, Fuchs B, et al. Pharmaceutical cancer care for haematology patients on oral anticancer drugs: Findings from an economic, clinical and organisational analysis. Eur J Cancer Care 2022; 31: e13753.","journal-title":"Eur J Cancer Care"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40780-024-00403-4"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S106629"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2018.7098"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djz244"},{"key":"e_1_3_2_34_2","first-page":"129","article-title":"Oral anticancer agent (OAA)","volume":"168","author":"Dinan MA","year":"2022","unstructured":"Dinan MA, Wilson LE, Greiner MA, et al. Oral anticancer agent (OAA). Adherence and Survival in Elderly Patients With Metastatic Renal Cell Carcinoma (mRCC). Urology 2022; 168: 129\u2013136.","journal-title":"Adherence and Survival in Elderly Patients With Metastatic Renal Cell Carcinoma (mRCC). Urology"},{"key":"e_1_3_2_35_2","article-title":"A retrospective study comparing interventions by oncology and non-oncology pharmacists in outpatient chemotherapy","volume":"4","author":"Kaya M","year":"2021","unstructured":"Kaya M, Nakamura K, Nagamine M, et al. A retrospective study comparing interventions by oncology and non-oncology pharmacists in outpatient chemotherapy. Cancer Rep 2021; 4: e1371.","journal-title":"Cancer Rep"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdp469"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12955-017-0680-2"},{"key":"e_1_3_2_38_2","article-title":"Evaluation of the clinical effect of pharmacist intervention Results of patient education about breast cancer","volume":"3","author":"Farrag DK","year":"2020","unstructured":"Farrag DK, Sabri NA, Tawfik AS, et al. Evaluation of the clinical effect of pharmacist intervention Results of patient education about breast cancer. Eur J Oncol Pharm 2020; 3: e23.","journal-title":"Eur J Oncol Pharm"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40780-018-0105-3"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40122-021-00342-0"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552261481842","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552261481842","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552261481842","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T12:19:41Z","timestamp":1788178781000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552261481842"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,27]]},"references-count":39,"alternative-id":["10.1177\/10781552261481842"],"URL":"https:\/\/doi.org\/10.1177\/10781552261481842","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,27]]},"article-number":"10781552261481842"}}